A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs DS 8273 (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 29 Sep 2017 Status changed from active, no longer recruiting to discontinued as per business decision
- 10 Aug 2017 Planned End Date changed from 1 Dec 2018 to 22 Sep 2017.
- 10 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 22 Sep 2017.